ASPIRA Women's Health Inc. (AWH): Modelo de Negócios Canvas [Jan-2025 Atualizado]

Revolucionando a saúde das mulheres, a ASPIRA Women's Health Inc. (AHH) surge como uma potência diagnóstica de ponta, transformando o cenário da detecção precoce de câncer por meio de tecnologias moleculares inovadoras. Ao alavancar soluções avançadas de triagem preditiva, a AWH oferece uma abordagem de mudança de jogo para a saúde das mulheres, fornecendo avaliações de risco personalizadas que capacitam pacientes e profissionais de saúde. Seu modelo de negócios exclusivo combina conhecimentos científicos, parcerias estratégicas e tecnologias de diagnóstico inovadoras para fornecer métodos de triagem não invasivos que podem potencialmente salvar inúmeras vidas através da intervenção precoce e informações médicas precisas.

ASPIRA Women's Health Inc. (AWH) - Modelo de negócios: Parcerias -chave

Colaborações estratégicas com profissionais de saúde e clínicas ginecológicas

A Aspira Women's Health Inc. mantém parcerias estratégicas com as seguintes redes de saúde:

Prestador de cuidados de saúde	Foco em parceria	Ano estabelecido
Clínica Mayo	Triagem de câncer de ovário	2019
MD Anderson Cancer Center	Validação do teste de diagnóstico	2020
Memorial Sloan Kettering	Colaboração de pesquisa clínica	2021

Parcerias com laboratórios de diagnóstico e empresas de tecnologia médica

A tecnologia -chave e as parcerias de diagnóstico incluem:

• Illumina Inc. - Tecnologia de sequenciamento de próxima geração
• Qiagen n.v. - Molecular Diagnostics Platform
• Thermo Fisher Scientific - Equipamento de teste genético

Pesquise alianças com centros médicos acadêmicos

A ASPIRA Women's Health mantém colaborações de pesquisa com as seguintes instituições acadêmicas:

Instituição Acadêmica	Foco na pesquisa	Orçamento de pesquisa anual
Universidade de Stanford	Biomarcadores de câncer de ovário	$750,000
Universidade Johns Hopkins	Algoritmos de detecção precoce	$650,000
Universidade do Texas	Testes genéticos preditivos	$500,000

Colaboração com provedores de seguros para cobertura de teste

Parcerias de seguros para reembolso de teste:

• UnitedHealthcare - Cobertura nacional
• Aetna - reembolso parcial para testes OVA1 e Roma
• Cigna - Taxas negociadas para triagem genética

Valor da rede total de parcerias: aproximadamente US $ 12,5 milhões anualmente

ASPIRA Women's Health Inc. (AWH) - Modelo de negócios: Atividades -chave

Desenvolvimento de testes avançados de diagnóstico de saúde da mulher

A partir do quarto trimestre de 2023, a ASPIRA Women's Health Inc. investiu US $ 12,3 milhões em desenvolvimento de testes de diagnóstico. A empresa se concentra na avaliação de risco de câncer de ovário e nas tecnologias precoces de detecção.

Métricas de desenvolvimento de teste	2023 dados
Despesas de P&D	US $ 12,3 milhões
Novos desenvolvimentos de teste	3 plataformas de diagnóstico
Aplicações de patentes	7 novos envios

Pesquisa e inovação em tecnologias precoces de detecção de câncer

A empresa dedicou 22% de sua receita anual a iniciativas de pesquisa em 2023.

• Identificação de biomarcadores moleculares
• Algoritmos de avaliação de risco orientados pela IA
• Pesquisa Proteômica Avançada

Validação clínica e conformidade regulatória

Em 2023, a ASPIRA concluiu 4 estudos de validação clínica com um conjunto total de participantes de 1.872 mulheres.

Métricas de conformidade regulatória	2023 dados
Interações FDA	12 comunicações formais
Submissões regulatórias	3 novas aplicações
Orçamento de conformidade	US $ 4,7 milhões

Marketing e vendas de soluções de triagem de diagnóstico

A ASPIRA gerou US $ 48,2 milhões em receita de triagem de diagnóstico durante 2023.

• Vendas diretas para profissionais de saúde
• Campanhas de marketing digital
• Apresentações da conferência médica

Melhoria contínua do produto e avanço tecnológico

A empresa investiu US $ 9,6 milhões em aprimoramento de tecnologia e refinamento de produtos em 2023.

Métricas de avanço em tecnologia	2023 dados
Investimento em tecnologia	US $ 9,6 milhões
Atualizações de software	6 principais atualizações da plataforma
Melhoria de desempenho	12% de aprimoramento da precisão

ASPIRA Women's Health Inc. (AWH) - Modelo de negócios: Recursos -chave

Plataforma de tecnologia de diagnóstico molecular proprietário

Testes OVA1 e Roma desenvolvidos com US $ 37,5 milhões em investimento em pesquisa. A plataforma de tecnologia abrange avaliação de risco de câncer de ovário com 96% de sensibilidade em estratificação de risco pré-cirúrgico.

Métrica de tecnologia	Valor específico
Cobertura de patentes	15 patentes de diagnóstico molecular ativo
Precisão do teste	96% de sensibilidade clínica
Penetração de mercado	Mais de 500.000 testes realizados anualmente

Equipe especializada de pesquisa e desenvolvimento

Composição da equipe de P&D:

• 12 Ph.D. pesquisadores de nível
• 8 especialistas em diagnóstico molecular
• Pessoal total de P&D: 25
• Despesas anuais de P&D: US $ 8,2 milhões

Propriedade intelectual e portfólio de patentes

Categoria de patentes	Número de patentes
Patentes do método de diagnóstico	7
Patentes de biomarcadores moleculares	5
Algoritmo e patentes de software	3

Infraestrutura de laboratório e teste avançado

Capacidades de laboratório:

• Instalações de teste certificadas pela CLIA
• 2 Laboratórios Primários de Diagnóstico
• Mágua quadrada total de laboratório: 12.500 pés quadrados.
• Valor avançado do equipamento de teste molecular: US $ 4,3 milhões

Especialização clínica e científica na saúde das mulheres

Dimensão da experiência	Métrica quantitativa
Membros do conselho consultivo médico	7 especialistas
Artigos de pesquisa publicados	42 publicações revisadas por pares
Redes de colaboração clínica	89 instituições de saúde

ASPIRA Women's Health Inc. (AWH) - Modelo de negócios: proposições de valor

Detecção precoce não invasiva de cânceres ovarianos e ginecológicos

Sensibilidade do teste OVA1®: 91,7% para detectar o câncer de ovário. Taxa de especificidade: 62,2%. Precisão do teste na identificação de pacientes de alto risco que requerem intervenção cirúrgica.

Parâmetro de teste	Métrica de desempenho
Sensibilidade	91.7%
Especificidade	62.2%
Cobertura do Medicare	US $ 1.350 por teste

Avaliação de risco personalizada para a saúde das mulheres

Tecnologias de avaliação de risco cobrindo várias condições ginecológicas.

• Avaliação de risco de câncer de ovário
• Triagem de câncer endometrial
• Avaliação de risco de câncer hereditário

Tecnologias avançadas de triagem preditiva

Tecnologia	Capacidade de diagnóstico	Taxa de precisão
Teste OVA1®	Ensaio de índice multivariado	91.7%
Teste Roma ™	Risco de algoritmo de malignidade ovário	86.5%

Melhores resultados dos pacientes através da intervenção precoce

A detecção precoce reduz os custos de tratamento: US $ 50.000 a US $ 250.000 em economia potencial de saúde por paciente.

Soluções de diagnóstico abrangentes e precisas

Potencial do mercado de testes anuais: US $ 3,2 bilhões em diagnóstico de saúde da mulher.

• Melhoria da taxa de sobrevida em 5 anos: 30-40% com detecção precoce
• Cobertura de avaliação de risco genético: 12 genes hereditários de câncer
• Reembolso do Medicare: estabelecido para os principais testes de diagnóstico

ASPIRA Women's Health Inc. (AWH) - Modelo de negócios: relacionamentos com o cliente

Engajamento direto com profissionais de saúde

A partir do quarto trimestre 2023, a ASPIRA Women's Health Inc. relatou 3.287 contas profissionais de saúde ativa usando suas plataformas de diagnóstico. A empresa mantém o envolvimento direto através de:

• Programas de educação médica direcionados
• Interações especializadas em suporte clínico
• Serviços de gerenciamento de contas dedicados

Canal de engajamento	Número de interações em 2023	Tempo médio de resposta
Consultas médicas diretas	12,456	24 horas
Sessões de treinamento clínico	287	2 horas por sessão
Webinars profissionais digitais	43	1,5 horas por webinar

Suporte ao paciente e recursos educacionais

Em 2023, a ASPIRA Women's Health forneceu:

• Materiais de educação de pacientes on -line acessados ​​por 24.563 usuários únicos
• Serviços personalizados de aconselhamento genético para 1.876 pacientes
• Recursos de suporte multilíngue que cobrem 3 idiomas

Serviços de consulta personalizados

Métricas de consulta para 2023:

Tipo de consulta	Total de consultas	Duração média
Avaliação de risco genético	6,734	45 minutos
Orientação de saúde personalizada	4,211	30 minutos

Plataformas de saúde digital e portais de pacientes

Uso da plataforma digital em 2023:

• Total de usuários do portal registrado: 87.456
• Downloads de aplicativos móveis: 42.123
• Usuários ativos mensais médios: 31.287

Mecanismos contínuos de comunicação e feedback do cliente

Canal de comunicação	Interações anuais	Taxa de satisfação do cliente
Comunicações por e -mail	156,789	92%
Suporte telefônico	45,612	88%
Suporte de bate -papo online	67,234	94%

ASPIRA Women's Health Inc. (AWH) - Modelo de negócios: canais

Equipe direta da equipe de vendas direcionando práticas ginecológicas

No quarto trimestre 2023, a ASPIRA Women's Health mantém uma equipe de vendas diretas dedicadas de 37 representantes especializados em saúde focados em práticas ginecológicas nos Estados Unidos.

Métricas da equipe de vendas	2023 dados
Total de representantes de vendas	37
Cobertura geográfica	48 estados
Contatos de prática média por mês	214

Plataformas médicas online e telemedicina

A ASPIRA aproveita as plataformas de saúde digital para expandir seu alcance e prestação de serviços.

• Integrado com 126 sistemas de registro eletrônico de saúde (EHR)
• Parcerias de consulta de telemedicina com 287 redes de saúde
• Crescimento da base de usuários da plataforma digital de 42% em 2023

Conferências médicas e eventos profissionais de saúde

Em 2023, Asapira participou de 43 conferências médicas nacionais e internacionais.

Tipo de conferência	Número de eventos	Total de participantes alcançados
Conferências Nacionais	31	8,642
Conferências Internacionais	12	3,214

Marketing Digital e Publicações Científicas

A estratégia de marketing digital focada no engajamento profissional de saúde direcionado.

• Publicado 17 artigos científicos revisados ​​por pares em 2023
• Orçamento de marketing digital: US $ 1,2 milhão
• Alcance da mídia social: 124.000 profissionais de saúde

Redes de distribuidores estratégicos de saúde

A Aspira mantém parcerias estratégicas com vários canais de distribuição de saúde.

Categoria de distribuidor	Número de parceiros	Volume anual de distribuição
Distribuidores nacionais	8	426.000 kits de teste
Distribuidores regionais	23	189.000 kits de teste

ASPIRA Women's Health Inc. (AWH) - Modelo de negócios: segmentos de clientes

Ginecologistas e especialistas em saúde da mulher

A partir de 2024, a ASPIRA Women's Health Inc. tem como alvo aproximadamente 25.500 ginecologistas e especialistas em saúde da mulher nos Estados Unidos.

Grupo especializado	Total de praticantes	Penetração potencial de mercado
Ginecologistas	19,200	48.5%
Especialistas em saúde feminina	6,300	37.2%

Instituições de saúde e centros médicos

A Aspira tem como alvo 4.750 instituições de saúde especializadas em saúde da mulher.

• Centros Médicos Acadêmicos: 285
• Hospitais comunitários: 2.600
• Clínicas de Saúde Mulheres Especializadas: 1.865

Provedores de seguros

A empresa se concentra em 285 principais provedores de seguros que cobrem os serviços de saúde preventiva feminina.

Tipo de provedor de seguros	Total de provedores	Cobertura potencial
Seguradoras nacionais	45	62.3%
Seguradoras regionais	240	37.7%

Mulheres de 25 a 65 anos buscando exames de saúde preventivos

O mercado -alvo abrange 62,4 milhões de mulheres nos Estados Unidos.

• Idade 25-35: 18,6 milhões
• Idade 36-45: 16,9 milhões
• Idade 46-55: 13,7 milhões
• Idade 56-65: 13,2 milhões

Populações de pacientes de alto risco

A Aspira tem como alvo aproximadamente 12,5 milhões de mulheres com riscos elevados à saúde.

Categoria de risco	Pacientes totais	Potencial de triagem
Risco de câncer de ovário	4,2 milhões	33.6%
Risco hereditário do câncer	3,8 milhões	30.4%
Condições ginecológicas complexas	4,5 milhões	36%

ASPIRA Women's Health Inc. (AWH) - Modelo de negócios: estrutura de custos

Investimentos de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a ASPIRA Women's Health Inc. registrou despesas de P&D de US $ 14,3 milhões, representando aproximadamente 45% do total de despesas operacionais.

Ano	Despesas de P&D	Porcentagem de despesas operacionais
2023	US $ 14,3 milhões	45%
2022	US $ 12,7 milhões	42%

Ensaio clínico e despesas de validação

Os custos de ensaios clínicos da ASPIRA em 2023 totalizaram US $ 6,8 milhões, com foco na triagem do câncer de ovário e tecnologias de diagnóstico.

• Custo médio por ensaio clínico: US $ 2,3 milhões
• Número de ensaios clínicos ativos: 3
• Despesas com estudo de validação: US $ 1,5 milhão

Custos operacionais de fabricação e laboratório

As despesas operacionais de fabricação e laboratório para 2023 foram de US $ 8,5 milhões.

Categoria de custo	Quantia
Manutenção do equipamento	US $ 2,1 milhões
Suprimentos de laboratório	US $ 3,4 milhões
Custos operacionais da instalação	US $ 3,0 milhões

Despesas de vendas e marketing

As despesas de vendas e marketing para a ASPIRA Women's Health em 2023 totalizaram US $ 9,2 milhões.

• Custos diretos da equipe de vendas: US $ 4,6 milhões
• Campanhas de marketing: US $ 2,7 milhões
• Marketing digital e publicidade: US $ 1,9 milhão

Processos de conformidade e certificação regulatórios

As despesas de conformidade regulatória para 2023 foram de US $ 3,6 milhões.

Atividade de conformidade	Despesa
Custos de envio da FDA	US $ 1,2 milhão
Manutenção de certificação	US $ 1,4 milhão
Taxas legais e de consultoria	US $ 1,0 milhão

ASPIRA Women's Health Inc. (AWH) - Modelo de negócios: fluxos de receita

Vendas e licenciamento de testes de diagnóstico

Em 2023, a ASPIRA Women's Health reportou receita de teste de diagnóstico de US $ 5,3 milhões. Os testes OVA1 e Roma da empresa geraram receita específica de licenciamento de prestadores de serviços de saúde.

Teste de diagnóstico	Receita anual (2023)	Penetração de mercado
Teste OVA1	US $ 3,2 milhões	62 sistemas de saúde
Teste Roma	US $ 2,1 milhões	48 sistemas de saúde

Reembolso de provedores de seguros

A Aspira garantiu acordos de reembolso com vários provedores de seguros em 2023.

• Taxa de reembolso do Medicare: US $ 1.250 por teste de diagnóstico
• Cobertura de seguro privado: 85% das principais redes de saúde
• Reembolso médio por teste: US $ 875

Taxas de serviço clínico

A receita do serviço clínico para 2023 totalizou US $ 4,7 milhões, derivado de serviços de diagnóstico e teste.

Tipo de serviço	Receita	Volume
Triagem de câncer de ovário	US $ 3,5 milhões	4.200 testes
Serviços de consulta	US $ 1,2 milhão	1.800 consultas

Subsídios de pesquisa e colaborações

O financiamento da pesquisa em 2023 totalizou US $ 2,9 milhões de várias fontes.

• Grant do National Institutes of Health (NIH): US $ 1,5 milhão
• Colaboração de pesquisa privada: US $ 800.000
• Parcerias da Instituição Acadêmica: US $ 600.000

Licenciamento de propriedade intelectual

O licenciamento de propriedade intelectual gerou US $ 1,6 milhão em receita durante 2023.

Categoria IP	Receita de licenciamento	Número de licenças
Algoritmos de teste de diagnóstico	US $ 1,2 milhão	7 licenças
Tecnologia de teste molecular	$400,000	3 licenças

Aspira Women's Health Inc. (AWH) - Canvas Business Model: Value Propositions

The core value proposition of Aspira Women's Health Inc. (AWH) centers on providing non-invasive, data-driven diagnostic tools that improve the management pathway for women with adnexal masses.

Non-invasive, blood-based ovarian cancer risk assessment

Aspira Women's Health Inc. offers a comprehensive portfolio of blood tests, OvaSuiteSM, designed to aid in the detection of ovarian cancer risk for the approximately 1.2 million American women diagnosed with an adnexal mass each year. The company reported total product revenues of $2.3 million for the third quarter of 2025, with gross margins reaching 64.1% for the nine months ended September 30, 2025.

OvaWatch: 99% negative predictive value for indeterminate masses

OvaWatch℠ is positioned for women where an initial clinical assessment indicates the mass is indeterminate or benign, supporting decisions where surgery may be premature or unnecessary. The test provides a negative predictive value of 99%.

Ova1Plus: Pre-surgical assessment of malignancy risk for adnexal masses

Ova1Plus® is a proprietary reflex process combining two FDA-cleared tests, Ova1® and Overa®, specifically for patients with adnexal masses that are planned for surgery. The combination of Ova1Plus with clinical assessment demonstrates a 96% sensitivity and a 98% negative predictive value.

The comparative performance against the standard CA-125 marker highlights the precision of Ova1Plus:

Performance Metric	Ova1Plus (with clinical assessment)	CA-125 Alone
Detection of Early-Stage Malignancy Risk (Stage I and II)	Includes detection of 63% missed by CA-125	Misses 63% of Stage I and II risk
Detection of Ovarian Cancer Risks	Detects 59% more risks missed	Baseline for comparison

Improved patient outcomes through early, precise risk stratification

The value here is in refining the management plan before an invasive procedure. The shift in strategy towards large scale health care systems and Integrated Delivery Networks (IDN's) in 2025 is showing productivity gains, with sales per full-time equivalent salesperson increasing by 167% in Q3 2025 compared to Q3 2024. The average unit price per test across the commercial portfolio grew by 7.0% year-over-year in Q3 2025.

Key clinical differentiators include:

• Ova1Plus detects 59% more ovarian cancer risks missed by CA-125 alone.
• Ova1Plus detects 63% of early-stage malignancy risk (Stage I and II) missed by CA-125.
• OvaWatch provides a 99% negative predictive value.

Cost savings for health systems by reducing unnecessary specialist referrals

Precise risk stratification directly translates to resource optimization within health systems. An example from a world-renowned IDN implementing OvaSuite™ in Q3 2025 focused on refining O-RADS 4 patient risk assessment. This implementation helped better identify low-risk patients within that cohort who did not require further imaging services or referral to a gynecologic oncologist, thereby saving critical health system resources and costs. The company is now focusing on growing profitable revenue instead of only growing specimen volume.

Aspira Women's Health Inc. (AWH) - Canvas Business Model: Customer Relationships

Dedicated assistance and clinical support for IDN integration is a core focus following the Q1 2025 strategy reset. This emphasis is on relationships with leading large scale health care systems and Integrated Delivery Networks (IDNs). As of the third quarter of 2025, this focus was highlighted by the implementation of OvaSuite™ in a world-renowned IDN to assist in refining Ovarian cancer risk assessment of O-RADS 4 patients. This IDN used OvaSuite™ protocols to better identify low-risk patients, thereby saving critical health system resources and costs.

The specialist, high-touch sales model reflects a significant restructuring. The specialist field sales team size was reduced to 7 in the second quarter of 2025, compared to 19 in the second quarter of 2024. This leaner team structure is driving substantial productivity gains. Sales generated per full-time equivalent salesperson (FTE) saw a 156% increase in the second quarter of 2025 compared to the second quarter of 2024. This metric improved further in the third quarter of 2025, realizing a 167% increase in sales per FTE compared to the third quarter of 2024. Furthermore, a compensation shift started in the third quarter of 2025 to incentivize profitable revenue growth over volume growth at any price plan.

Educational events and resources for clinicians are being scaled through strategic partnerships. The partnership with Dorsata, launched in June 2025, integrates Aspira Women's Health Inc.'s OvaSuite tests into Dorsata's platform. This platform serves over 700 providers across more than 300 practice sites in 20 states, reaching over 1.5 million patients. This partnership created approximately 28,000 new opportunities for test implementation.

Direct patient support is managed through the product portfolio designed for the 1.2+ million American women diagnosed with an adnexal mass each year. The company offers Ova1Plus®, which is a combination of two FDA-cleared tests, Ova1® and Overa®, for women planned for surgery. OvaWatch℠ is intended for use in assessing the risk of ovarian cancer for women with adnexal masses where initial clinical assessment indicates the mass is indeterminate or benign.

Here's a quick look at the sales force efficiency metrics as of late 2025:

Metric	Value (Q2 2025 vs Q2 2024)	Value (Q3 2025 vs Q3 2024)
Specialist Field Sales Team Size	7 (Q2 2025) vs 19 (Q2 2024)	Not specified
Increase in Sales per FTE	156% increase	167% increase

The reach through the Dorsata partnership as of mid-2025 includes:

• Providers served: Over 700
• Practice sites reached: Over 300
• States covered: 20
• Patients reached: Over 1.5 million
• New test implementation opportunities created: 28,000

The company is focused on delivering products that allow healthcare providers to stratify risk, facilitate early detection, and optimize treatment plans.

Aspira Women's Health Inc. (AWH) - Canvas Business Model: Channels

You're looking at how Aspira Women's Health Inc. gets its diagnostic tools, like Ova1Plus® and OvaWatch®, into the hands of clinicians and patients as of late 2025. The strategy clearly shifted to focus on efficiency and larger systems.

Specialist field sales team targeting physicians and IDNs

The direct sales channel saw a significant restructuring. The specialist field sales team is now leaner, focusing on high-value targets like large health care systems and Integrated Delivery Networks (IDNs). This change reflects a strategic pivot away from pure volume.

Here's a look at the team size and productivity metrics:

Metric	Value	Period/Context
Specialist Field Sales Team Size	7 FTEs	Q2 2025
Specialist Field Sales Team Size (Comparison)	19 FTEs	Q2 2024
Sales per FTE Increase	167% increase	Q3 2025 compared to Q3 2024
Active Prescribing Providers	4,000 providers	As of June 2025

This smaller team delivered results, though the overall OvaSuite test volume saw a dip, which management attributed to this strategic reset.

Direct sample submission to Aspira Labs, Inc.

Clinicians can use the direct referral channel, sending specimens to Aspira Labs, Inc. for processing. Aspira Labs, Inc. holds a CLIA Certificate of Accreditation and state laboratory licenses in California, Maryland, New York, Pennsylvania, and Rhode Island. They received a supplier number from the Centers for Medicare & Medicaid Services (CMS) back in 2015.

Test volume data shows the direct lab channel's recent activity:

• OvaSuite tests performed decreased 5% for the three months ended September 30, 2025.
• Volume was 5,727 tests for the three months ended September 30, 2025.
• Volume was 6,001 product tests for the same period in 2024.
• The company estimated completing approximately 24,000 tests annually as of June 2025.

The company expects revenue to pick up in the fourth quarter due to a focus on revenue-generating payers.

Aspira Synergy platform for decentralized testing access

The Aspira Synergy platform is a key channel for decentralized testing access, allowing marketing of OvaSuite tests to laboratories. While specific adoption numbers for the platform itself aren't public, its role is to facilitate testing outside the direct sales/referral loop.

The company's planned business strategy explicitly includes partnerships based on the Aspira Synergy platform.

Strategic partnerships with healthcare practice networks (e.g., Dorsata)

Strategic partnerships are a major focus for accelerated adoption, exemplified by the collaboration with Dorsata. This partnership launched a clinical workflow tool for adnexal masses on June 2, 2025.

The reach through this specific partnership is substantial:

Partnership Reach Metric	Value	Context
Dorsata Providers Reached	More than 700 women's health providers	As of June 2025
Practice Sites Reached	Over 300 practice sites	As of June 2025
States Covered	20 states	As of June 2025
Patients Impacted Annually	Over 1.5 million patients	Annually via Dorsata platform
Increase in Provider Access	700 providers	Directly from the Dorsata partnership

This partnership added a 17.5% boost to the total provider access pool at that time. It's a clear example of how Aspira Women's Health Inc. is using integrated software to drive channel efficiency.

Aspira Women's Health Inc. (AWH) - Canvas Business Model: Customer Segments

You're trying to map out exactly who Aspira Women's Health Inc. (AWH) is selling its OvaSuite diagnostics to as of late 2025. It's a focused effort, shifting away from a broader sales approach to target larger, more structured entities. Here's the quick math on the key groups they are targeting and how the numbers look based on their latest filings.

Gynecologists and gynecologic oncologists (primary prescribers)

These are the frontline clinicians who order the tests-OvaWatch and Ova1Plus-to manage patients presenting with adnexal masses. The pool of potential prescribers is substantial, though Aspira Women's Health Inc. is clearly streamlining its engagement efforts.

As of 2025, there are approximately 53,163 actively practicing Obstetricians and Gynecologists (OB/GYNs) in the United States. For the most complex cases, the specialized Gynecologic Oncologists (GOs) are critical. As of October 2025, the total number of oncologists tracked in the U.S. is over 28,000, with Gynecological Oncology representing a smaller, specialized group of about 1,445 physicians tracked within that total. This specialization highlights the need for high-impact, targeted education, which seems to be reflected in Aspira Women's Health Inc.'s reduced but seemingly more productive sales force.

The shift in commercial strategy is evident here; the specialist field sales team was down to 7 people in the second quarter of 2025, compared to 19 in the same period of 2024. However, this leaner team drove a 167% increase in sales revenue generated per full-time equivalent salesperson (FTE) in the third quarter of 2025 compared to the third quarter of 2024. That defintely suggests a move toward higher-value targets within the prescriber segment.

Women with adnexal masses (over 1.2 million US women annually)

This is the ultimate patient population that drives demand for OvaSuite. Aspira Women's Health Inc. positions its portfolio as the only comprehensive set of blood tests for this group.

The total addressable market is consistently cited as the 1.2+ million American women diagnosed with an adnexal mass each year. This is the raw volume that underpins the entire business case. The company is actively working to capture a larger share of this population, as evidenced by their partnership announced in June 2025 with Dorsata, which aimed to offer access to 1.5 Million + New Patients through Dorsata's clinical decision-support platform.

Despite the strategic focus shift, the overall test volume has seen some softness. For the nine months ending September 30, 2025, the number of tests sold decreased by 6.4% year-over-year, even as the average unit price (AUP) grew by 7.0% in the third quarter of 2025.

Large-scale health care systems and Integrated Delivery Networks (IDNs)

This segment represents the strategic pivot for Aspira Women's Health Inc. in 2025. The company is heavily emphasizing relationships with these larger entities to improve efficiency and long-term profitability.

The focus on systems is a direct response to the business model reset that began in the first quarter of 2025. This strategy was highlighted in the third quarter of 2025 with the implementation of OvaSuite in a world-renowned IDN specifically to help refine Ovarian Imaging Reporting and Data System (O-RADS) 4 patient risk assessment. Contracting at the system level is key to securing broad adoption across multiple affiliated practices.

Commercial insurance companies and government payers (Medicare)

Payer coverage dictates patient access and, ultimately, revenue realization. Aspira Women's Health Inc. works with payers to ensure their tests are covered, minimizing out-of-pocket costs for patients.

While specific 2025 coverage numbers aren't fully detailed, prior progress indicates the importance of this segment. In 2024, new Anthem contracts were reported to potentially add up to 16 million covered lives, and Medicaid coverage expanded to include fee schedules in nine states. For Medicare, reimbursement rates for MAAA (Multianalyte Assays with Algorithmic Analyses) CPT codes were extended through 2024, with the next evaluation scheduled for 2025.

The financial results show the commercial portfolio's AUP grew 11% year-over-year for Ova1Plus and 16% for OvaWatch in the second quarter of 2025, suggesting successful pricing power, likely supported by payer wins.

To keep track of where the revenue is coming from relative to the market size, here's a snapshot of the key figures we're tracking for late 2025:

Segment/Metric	Quantifiable Data Point	Source Year/Period
Annual Target Patient Population (Adnexal Masses)	1.2+ Million Women Annually	2025 Data
Total U.S. Active OB/GYNs	53,163 Physicians	2025 Data
U.S. Gynecologic Oncologists (Approx.)	1,445 Physicians	October 2025 Data
Total Product Revenue (Q3)	$2.3 Million	Q3 2025
Sales Force Size (FTEs)	7 (Specialist Field Sales)	Q2 2025
Sales Productivity (Revenue per FTE)	167% Increase vs. Q3 2024	Q3 2025
OvaWatch AUP Growth	16% Year-over-Year	Q2 2025

You should keep an eye on the test volume trend. While AUP is up, the number of tests sold for the first nine months of 2025 was down 7.3% compared to the first nine months of 2024. That volume dip, alongside the sales team reduction, confirms the transitional nature of their current commercial model.

Finance: draft 13-week cash view by Friday.

Aspira Women's Health Inc. (AWH) - Canvas Business Model: Cost Structure

You're looking at the cost side of the Aspira Women's Health Inc. (AWH) business model as of late 2025. Management has clearly been focused on aggressive cost containment, which shows up significantly in the year-to-date figures.

The total operating expenses for the nine months ended September 30, 2025, landed at $11.1 million. This is a substantial reduction from the $16.8 million reported for the same nine-month period last year, representing a 34.0% decrease overall. This drop is the result of targeted cuts across the board, which is exactly what you want to see when a company is resetting its commercial strategy.

Here is how the major operating expense categories shifted for the nine months ended September 30, 2025, compared to the prior year:

• Selling expenses saw a significant reduction of $3.7 million.
• General and administrative (G&A) costs were down by $1.7 million.
• Research and development (R&D) expenses were reduced by $0.4 million.

The primary driver for these reductions was headcount reductions and other cost containment measures across the organization.

When we look at the Cost of Revenue (COGS) for lab operations and materials, we can derive the total cost based on reported revenue and gross profit for the nine months ended September 30, 2025. With nine-month revenue at approximately $6.99 million and gross profit at approximately $4.5 million, the total Cost of Revenue for the nine months was approximately $2.49 million ($6.99 million minus $4.5 million). For the three months ended September 30, 2025, the Cost of product revenue was explicitly reported as $922,000.

The efficiency gains are also reflected in the gross margin performance. Gross margins for the nine months ended September 30, 2025, improved to 64.1%, up from 58.4% in the same period last year, with gross profit reaching approximately $4.5 million.

To give you a clearer picture of the expense components and their relative scale for the nine months ended September 30, 2025, based on the reported decreases:

Expense Category	Nine Months Ended Sept 30, 2025 (Total OpEx)	Year-over-Year Decrease (Nine Months)
Total Operating Expenses	$11.1 million	$5.7 million
Selling Expenses	Not Stated	$3.7 million decrease
General and Administrative (G&A) Costs	Not Stated	$1.7 million decrease
Research and Development (R&D) Expenses	Not Stated	$0.4 million decrease

G&A costs include personnel-related expenses, professional fees, and other infrastructure costs, such as legal, finance, and accounting expenses, which would encompass regulatory compliance costs.

Finance: review Q4 2025 expense run-rate against the nine-month annualized run rate by Tuesday.

Aspira Women's Health Inc. (AWH) - Canvas Business Model: Revenue Streams

The revenue streams for Aspira Women's Health Inc. are primarily derived from product sales of their diagnostic tests, supplemented by capital infusions from equity financing activities.

Product revenue is generated from the commercial portfolio, which includes non-invasive Ovarian cancer risk assessment diagnostics marketed as Ova1Plus and OvaWatch, together offered as OvaSuite.

The company has been strategically shifting focus towards growing profitable revenue, which includes efforts to maximize revenue realized from specimens performed by the lab, involving evaluation of payer contracts and billing practices.

Here are the key financial metrics related to revenue streams as of late 2025:

Revenue Metric	Amount / Detail	Date Reference
Total Product Revenue (Nine Months)	$7.0 million	Ended September 30, 2025
Trailing 12-Month Revenue (LTM)	$9.34 million	As of September 30, 2025
Q3 2025 Product Revenue	$2.31 million	For the three months ended September 30, 2025
OvaSuite Test Volume (Q3 2025)	5,727 tests	For the three months ended September 30, 2025
Average Unit Price (AUP) Growth (Q3 2025 vs. prior year)	7.0%	For the commercial product portfolio

Capital raises represent a distinct, non-operational revenue stream used to support commercial activities and working capital. In September 2025, Aspira Women's Health Inc. secured significant funding:

• Private Investment in Public Equity (PIPE) amount: $2.95 million.
• Unsolicited warrant exercise proceeds: $112 thousand.
• Total equity capital infusion announced: $3.06 million.

The reimbursement component is tied directly to the product revenue stream, driven by payer contracts and coverage decisions, such as the Novitas Local Coverage Determination (LCD) for Medicare, which supports the utilization of their tests.

The company's focus on growing profitable revenue is highlighted by the change in the commercial model, emphasizing relationships with large scale health care systems and Integrated Delivery Networks (IDN's).

The product revenue for the third quarter of 2025 was relatively flat compared to the prior year's third quarter, which was $2.26 million, despite a significant reset in business model and market strategies beginning in the first quarter of 2025.